Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1301 to 1350 of 4091 results for patient

  1. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

  2. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  3. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  4. Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

  5. Past research and projects

    NICE's past research and projects

  6. XprESS multi sinus dilation system for treating chronic sinusitis (HTG424)

    Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.

  7. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

  8. Gallstone disease (QS104)

    This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.

  9. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  10. Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)

    Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.

  11. Cryoablation for atrial fibrillation in association with other cardiac surgery (HTG74)

    Evidence-based recommendations on cryoablation for atrial fibrillation in association with other cardiac surgery. This involves using a probe to freeze the heart tissue to scar it and interrupt the abnormal electrical signals.

  12. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  13. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

  14. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

  15. Antimicrobial stewardship (QS121)

    This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.

  16. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  17. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's (HTG733)

    Evidence-based recommendations on MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson’s. This involves using ultrasound to destroy tissue in the thalamus.

  18. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  19. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  20. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).

  21. Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse (HTG435)

    Evidence-based recommendations on sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. This involves attaching mesh from the top of the vagina to the base of the spine to support the pelvic organs after the womb has been removed.

  22. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

  23. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

  24. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

  25. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (HTG297)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  26. Incisionless otoplasty (HTG283)

    Evidence-based recommendations on incisionless otoplasty. This involves using a hollow needle to divide the ear cartilage, and using stitches buried under the skin to remould the ear.

  27. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  28. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

  29. Constipation in children and young people (QS62)

    This quality standard covers the diagnosis and management of constipation of unknown cause in babies, children and young people (from birth to 18 years). It describes high-quality care in priority areas for improvement.

  30. Percutaneous endoscopic colostomy (HTG105)

    Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.

  31. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

  32. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

  33. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  34. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

  35. Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.

  36. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

  37. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)

    Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.

  38. Low dose rate brachytherapy for localised prostate cancer (HTG81)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

  39. Key question: safe

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  40. Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (HTG300)

    Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.

  41. Open femoro–acetabular surgery for hip impingement syndrome (HTG270)

    Evidence-based recommendations on open femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  42. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

  43. Photodynamic endometrial ablation (HTG23)

    Evidence-based recommendations on photodynamic endometrial ablation. This involves using a light-sensitive chemical and laser to destroy the endometrium.

  44. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

  45. Microwave ablation for treating liver metastases (HTG409)

    Evidence-based recommendations on microwave ablation for treating liver metastases in adults. This involves using heat energy to destroy cancer cells.

  46. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

  47. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

  48. Laparoscopic repair of abdominal aortic aneurysm (HTG147)

    Evidence-based recommendations on laparoscopic repair of abdominal aortic aneurysm. This involves replacing the damaged parts of the aorta with an artificial piece of blood vessel, performed through small cuts in the abdomen (keyhole surgery).

  49. Self-harm: assessment, management and preventing recurrence (NG225)

    This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.